drugset
drugset / Trial / NCT03886948

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948 ↗

Phase 1 Completed 66 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.

Timeline

Start
2019-03-27
Primary completion
2019-10-04
Completion
2019-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirikizumab Monoclonal antibody 125 mg Subcutaneous

Indications

No indication recorded.